Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. - Wikidata - awgldk - TriplyDB

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

http://www.wikidata.org/entity/Q36483161

about

Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Neutrophil count is associated with survival in localized prostate cancer Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer.Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel Inflammation and prostate cancer: friends or foe?Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.The prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer: Deleterious or advantageous?The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.Neutrophil to lymphocyte ratio and its association with tumor prognosis in systemic malignancies.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme.Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.Impact of neutrophil-lymphocyte ratio on long-term outcome in patients with craniopharyngioma Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy

P2860

Q26765951-CD604866-D273-4702-B636-4EE9ABD57E42 Q26773406-DE38A37F-1C89-4D06-A4AE-9A334F2FBA77 Q26786160-A4F61C7B-967C-4047-A963-337864965207 Q27009534-8940D99C-CF8E-4E2E-9F0D-0304FBDF215E Q27022482-638A828D-3ADF-4C50-AFFA-B3A8BA4BB802 Q35274955-83A7EE4A-53BD-4D59-A307-A26DEF5F7A6D Q35586693-D0B0B61C-47C1-4C7E-995B-0919861AE861 Q35751637-1B808BEE-C0FB-429C-8C16-5A0FBC931A6C Q35790197-F4E7720C-D62C-4656-86C0-F907525E8A4F Q36081801-E29A3C6C-EEC5-4653-B3FA-0FAFBFACC8DC Q36416408-4A9EF2F4-4708-4EC1-BF8A-26014B40D72C Q38383521-916D4C6C-2966-4570-9ED1-7ECAF7D6C691 Q38978620-6AE26C21-98F4-45CA-8658-5AF77651B0CF Q39050892-BA0936F0-9918-46A3-976D-BFB0EDFDFFF0 Q39250942-26D2F9FC-2BD9-4BB1-ACAA-B718E0C0D9A9 Q39400399-E60C471A-B09A-44D3-BE1A-8B810E8C7270 Q40332155-66E6E655-3703-4DEC-9D41-4B65B0FBF8B4 Q40723187-5958D6BC-4C43-4840-B672-0D23CA6C5E73 Q41777743-5C45BFBF-1CC1-4193-9B79-FF763FABBF1F Q43405764-D2253898-F326-45C9-98BD-34672CDD5B0B Q45287349-6D59E66C-02E7-4207-9782-76A076557233 Q46833943-C4C3088B-0E71-41EB-915D-DD638DF19E5C Q47563950-C0EF9705-9885-4CA7-A7BD-2E83F0FF9045 Q51712236-3E71A7A4-F560-4D66-BB58-3D23AF5E96F3 Q53036812-5A46C6EC-75F4-45B9-889E-8FBD0462E2DF Q53036820-041D62B1-6647-497E-BBA8-B286D8A7244A Q53822455-0F9BA577-941E-4B6D-9E07-E7B66FBEE2DC Q58739379-5396225E-CDA3-481A-9C69-8BEC89C937FC Q58801937-4C16CB04-4B22-48BE-892D-F4EBABD612D5

P2860

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

http://www.wikidata.org/entity/Q36483161

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@ast

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@en

type

label

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@ast

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@en

prefLabel

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@ast

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@en

P1433

Q36483161-2D7B53B5-826A-432E-B6C7-FE072E9EE229

P1476

Q36483161-7C1DBE68-B91D-4D8D-8506-D7345A9EAF89

P2093

Q36483161-1A4FB347-6A02-40F6-A9DE-C1208F85EE3C

Q36483161-1F7C4F7B-00BA-4EBE-A84A-E6259851FB8C

Q36483161-56CAE399-892B-4C1A-9968-9FCEED3EE37E

Q36483161-59D48202-B164-44C9-93D6-3C515389A112

Q36483161-666843E4-574D-42C2-B201-EC547F813100

Q36483161-69814629-5215-4577-B11C-791DA460934C

Q36483161-70685ED5-9006-4C0D-814B-67E926B928E3

Q36483161-7DCFACE9-79B1-4898-83F7-B81DF02E9DB5

Q36483161-94291053-36F0-4FCE-8804-1F849A382C15

Q36483161-B16ED6E8-D9A4-4039-9283-C9329A026720

P2860

Q36483161-02B3B08B-FABF-4ADC-88C3-9BC34A120574

Q36483161-056EADEB-805C-4CFA-95B3-8F078B604B52

Q36483161-0F2F0019-46C1-4AAA-B80C-15A4693EDA24

Q36483161-2A85E31D-1877-4D44-9BC0-6BA0ECEF4825

Q36483161-2F67BBCF-31BA-412C-968D-EF475772AFC4

Q36483161-41F2D0FA-DEDD-4995-9E0F-836A7652BCC6

Q36483161-47C733A6-9E08-4737-9EBA-483D57DC94EC

Q36483161-49EBCE69-F99B-442B-A126-C4630E96C94C

Q36483161-4DD05E50-4914-4DF3-8F4B-102270C733E6

Q36483161-5316FEBE-0A82-4323-9F68-6ADC513054CE

P304

Q36483161-DF89FCE9-B2FF-4D37-9A96-F900D02E76D0

P31

Q36483161-548B3932-EBD0-444D-8C42-91433AFC5A7F

P356

Q36483161-50131FB2-9A67-4D7B-A77B-B968346BBD22

P433

Q36483161-03CE414F-4581-40FB-9A4F-252A1CFC0B6F

P478

Q36483161-4B912054-5E3C-4796-AB0F-6CA85499D0AB

P577

Q36483161-E2D4A158-C292-4374-95BE-5DAA8F3B4611

P5875

Q36483161-2A9AB743-5834-4CAB-9CD8-62AD2E29342C

P698

Q36483161-59BB2375-E5CE-45CC-BAA1-772E0F5D0C4E

P921

Q36483161-8A20C1AC-FC61-4C5D-A50F-1C7DDC1FEFB4

P932

Q36483161-9BD5B673-4A35-473C-AF7A-1C09912A733A

P356

THEONCOLOGIST.2012-0125

P1433

P1476

Pretreatment neutrophil-to-lym ...... tcome and predictive nomogram.

@en

P2093

Avishay Sella

http://www.w3.org/2001/XMLSchema#string

Avivit Neumann

http://www.w3.org/2001/XMLSchema#string

Avivit Peer

http://www.w3.org/2001/XMLSchema#string

Daniel Keizman

http://www.w3.org/2001/XMLSchema#string

Eli Rosenbaum

http://www.w3.org/2001/XMLSchema#string

Hans Hammers

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

Maya Gottfried

http://www.w3.org/2001/XMLSchema#string

Maya Ish-Shalom

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Cancer-related inflammation

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Natural history of progression after PSA elevation following radical prostatectomy.

Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

P304

1508-1514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0125

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230841190

http://www.w3.org/2001/XMLSchema#string

P698

22971522

http://www.w3.org/2001/XMLSchema#string

P921

P932

3528383

http://www.w3.org/2001/XMLSchema#string